Compass Therapeutics

Compass Therapeutics

  • Founded: 2013
  • Location: Boston, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: Biliary tract carcinoma
  • Drug types: ONC, IMM
  • Lead product: CTX-009
  • Product link:
  • Funding: $80M stock Nov 2022; $125M stock Oct 2021; $60M stock Jun 2020; $132M A Jun 2015-Jul 2018

job board

Short description:

Antibody Therapies

Drug notes:

Also Clin1b colorectal cancer, Clin1b ovarian cancer; CTX-471 2 efforts Clin0/Clin1b oncology, CTX-8371 Clin0 oncology; undisclosed RD autoimmune condition

Long description:

Compass Therapeutics focuses on high-throughput screening of antibody therapeutics for cancer and autoimmune disorders using common light-chain platforms. Compass utilizes common light chains both in vivo and in vitro to produce diverse panels that are screened using next generation mammalian display filters with a turnaround time of 8 weeks from antigen to optimized monoclonal antibodies produced in cell culture. Compass’s StitchMabs technology also allows them to produce highly specific bi- and mutli-specific biologics. Bispecific biologics are screened in large matrices to increase the likelihood of discovering novel synergistic combinations. The Compass pipeline is focused on therapies aimed at either activating or releasing immune suppression of T cells, NK cells, and macrophages.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy